Latest filing published 08 Oct 2026 for 케이엠제약. Read the official filing
Based on 7 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
강일모 is a declared insider of 케이엠제약 (chief executive), with filings sourced from DART (FSS). The record holds 56 filings, for trades running from 15 April 2021 to 8 October 2026.
On the open market, the record shows 36 purchases worth €161k and 3 sales. The totals do not cover 32 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. 2026 to date brings 20 purchases and 2 sales.
The median purchase comes to €17k. Relative to company size, the median is 0.29% of market cap (7 purchases with a known value). Of 30 purchases, 5 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 7 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 29% of cases, with a median move of -25.4%. They describe history only and say nothing certain about the share price ahead.
The latest filing, published on 8 October 2026, reports a transaction in 케이엠제약. The last insider purchase was made public on 16 September 2026, 32 days ago. Typically, a trade is published a median of 5 days after it takes place. That lag is the time during which only the insider knows about the trade. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 56 declarations